HomeLYEL • NASDAQ
Lyell Immunopharma Inc
Follow
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 11.00K | -15.38% |
Operating expense | 61.75M | 4.52% |
Net income | -191.94M | -262.62% |
Net profit margin | -1.74M | -328.55% |
Earnings per share | -0.17 | 0.92% |
EBITDA | -56.72M | -5.00% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 370.53M | -32.17% |
Total assets | 490.86M | -34.55% |
Total liabilities | 108.04M | 13.63% |
Total equity | 382.82M | — |
Shares outstanding | 295.23M | — |
Price to book | 0.34 | — |
Return on assets | -27.81% | — |
Return on capital | -29.94% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -191.94M | -262.62% |
Cash from operations | -47.24M | -16.26% |
Cash from investing | 53.51M | 153.14% |
Cash from financing | 437.00K | -42.42% |
Net change in cash | 6.70M | 104.77% |
Free cash flow | -5.66M | 73.34% |
Previous close
$0.45
Day range
$0.40 - $0.48
Year range
$0.40 - $3.15
Market cap
117.79M USD
Avg Volume
853.39K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2018
Headquarters
Website
Employees
300
